Good Day BIO: What the banana tells us about our food systems

June 28, 2021
Start your week with a nutritious, delicious banana—while you still can. Today’s episode of the I am BIO Podcast explores the threat to bananas and what it tells us about our food systems. We also have news on a BARDA decision that would affect R&D of COVID…
BIO

Start your week with a nutritious, delicious banana—while you still can. Today’s episode of the I am BIO Podcast explores the threat to bananas and what it tells us about our food systems. We also have news on a BARDA decision that would affect R&D of COVID therapeutics as well as the bioeconomy bill moving through Congress. (797 words, 3 minutes, 59 seconds)

 

What the banana tells us about our food systems

 
 

The banana is the world’s most popular fruit—yet it could very soon go missing from our store shelves due to disease. In today’s episode of the I am BIO Podcast, we look at what the banana tells us about our food systems—and the role biotech can play in making them more resilient, sustainable, and accessible. 

The bananas we eat today are not the same bananas our great grandparents ate—because that banana, the Gros Michel, was wiped out by disease

The Cavendish bananas we eat today are now facing the same threat—which has been increasing over the last few years in Latin America, the source of nearly all imported bananas in the U.S. and Europe.

“The plight of the banana should be viewed as a warning sign,” says BIO’s Dr. Michelle McMurry-Heath—especially since no other banana variety has had the predictable growing and ripening pattern, taste, and strength for easy transport. 

Genetic engineering could help—by improving disease resistance, explains Dan Koeppel, author of Banana: The Fate of the Fruit that Changed the World

Biotech can also improve pesticides. 40% of crop yields use some form of crop protection (pesticides)—but many are being pulled from the market or don’t control pests like they used to. Vestaron is creating biopesticides with the same efficacy as those made with synthetic chemicals—and are safe for bees and animals and don’t leave residue in soil or watersheds.   

Transparency and education are key to making these solutions a reality. “It’s important for people to understand what science actually does,” and we need to explain the methods and the benefits, Agriculture Secretary Tom Vilsack said during BIO Digital

But we need to act quickly. Hunger and poverty continue to increase worldwide—and the banana is just one food that’s under threat. Biotechnology has to be part of the conversation. 

Listen to the whole thing.

 

More Agriculture and Environment News: 

CNBC: U.S. Supreme Court backs refineries in biofuel waiver dispute
“The 6-3 ruling overturned a lower court decision that had faulted the U.S. Environmental Protection Agency for giving refineries in Wyoming, Utah and Oklahoma extensions on waivers from renewable fuel standard (RFS) requirements under a law called the Clean Air Act.”

 
 
 
Twitter
 
LinkedIn
 
Facebook
 
 
 
 

As BIO's preferred corporate credit card for life sciences, Brex comes with automated expenses, higher limits than traditional credit cards, and tailored rewards on lab supplies, and more.

Brex is offering an exclusive offer of 60,000 sign-up bonus points and waived card fees for life for members. 

Learn more about BIO-BREX benefits today. 

 
 
 
Twitter
 
LinkedIn
 
Facebook
 
 

Why we need to keep investing in COVID therapeutics, too

 
 

A May 2021 change to the Biomedical Advanced Research and Development Agency (BARDA) Broad Agency Announcement (BAA) suspends prioritization of COVID-19 therapeutics—a premature decision, says BIO President and CEO Dr. Michelle McMurry-Heath.

COVID-19 therapeutics have reduced hospitalization and death during the pandemic—particularly antibody cocktails like those from Regeneron/Roche and GlaxoSmithKline/Vir.

And industry partnerships with BARDA have been key to developing COVID-19 countermeasures—as well as vaccines and therapeutics for other threats like pandemic influenza, smallpox, and anthrax, to name a few. 

But the COVID-19 pandemic’s not over yet—and we need more therapeutics. COVID-19 cases are expected to rise again this winter and public health leaders anticipate we will see moderate and severe cases that require treatment and possible hospitalization. 

This is why it’s premature to deprioritize advanced R&D and procurement of therapeutics,BIO’s Dr. Michelle McMurry-Heath wrote in a letter to Health and Human Services (HHS) Secretary Xavier Becerra

“Continuous investment in a broader portfolio of COVID-19 therapeutics will facilitate access to new medical countermeasures through easier routes of administration, fewer potential doses, or more specific impact on clinical outcomes,” which will improve equity of treatment. It will also help deal with secondary effects like “long COVID,” as well as new variants of concern.

“Finally, finishing the job with COVID-19 therapeutics will have applicability to our ability to rapidly respond to infectious disease threats in the future,” she continues. 

The bottom line: We need a strategy for continued development of COVID-19 therapeutics. Such a strategy is critical for industry partners in their research planning—and critical as we prepare to respond to new outbreaks and variants.

Read the whole letter.

See what’s in the COVID-19 therapeutic pipeline.

P.S. Are you working on innovations related to orthopedic joint replacement surgery? Johnson & Johnson’s JLabs launched a QuickFire Challenge to award up to $50,000 in grant funding for outside-the-box innovations from healthcare as well as the broader robotics and technology industry with potential applications in the OR. JLABS is accepting applications through today—get the details on this opportunity as well as other open opportunities.

 
 
 
Twitter
 
LinkedIn
 
Facebook
 
 
BIO Beltway Report
BIO Beltway Report
 
Paragraph (sm) - Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Quis ipsum suspendisse ultrices gravida. Risus commodo viverra maecenas accumsan lacus vel facilisis sample link.
 

President Biden’s Monday: Meeting with President of Israel Reuven Rivlin at the White House. Meanwhile, Axios says Biden’s climate clock is ticking

What’s Happening on Capitol Hill: The House will consider National Science Foundation (NSF) for the Future Act (H.R. 2225), the companion bill to the U.S. Innovation and Competition Act of 2021 (S. 1260), which recently passed the Senate. Formerly known as the Endless Frontier Act, this bill would boost R&D and the bioeconomy—and BIO supports it.

 
 
Paragraph (normal) - Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Quis ipsum suspendisse ultrices gravida. Risus commodo viverra maecenas accumsan lacus sample link.
 
Twitter
 
LinkedIn
 
Facebook